A phase I trial demonstrated a significant reduction in macrophage number in solid tumors after anti-Csf-1r treatment (152), and Csf-1r inhibition showed an improvement in clinical outcomes including improvement of symptoms in patients with diffuse-type giant cell tumors (153). The gene discussed is CSF2; the disease is tenosynovial giant cell tumor, diffuse type.